The Medical University of Warsaw together with the National Institute of Oncology - National Research Institute and the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences have begun to participate in a new consortium project "INTEGRATED SERVICES FOR INFECTIOUS DISEASES OUTBREAK RESEARCH" (ISIDORe). Funded by the Horizon Europe Framework Programme, ISIDORe involves the most prestigious research units from 32 countries.
The aim of the project is to establish an international research infrastructure for the rapid development of agents directed against novel variants of the SARS-CoV-2 coronavirus and other pathogens with pandemic potential. The coordinator of the activities within the ISIDORe project at our university is Radosław Zagożdżon, MD, PhD, head of the Department of Clinical Immunology MUW. The work of our scientists will be connected with the evaluation of antiviral efficacy of new nanobodies developed in cooperation with NIO-PIB and IBB PAN.
The European Commission has allocated €21 million for research. This amount can be increased depending on the needs and emerging risks. The project implementation period is 3 years.